http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008106902-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-02 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
filingDate | 2006-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2009-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2008106902-A |
titleOfInvention | APPLICATION OF A ONE DOSE OF CD20-SPECIFIC BINDING MOLECULES |
abstract | 1. A method of treating a person having or presumably having a disease associated with aberrant B-cell activity, comprising administering to a person a therapeutically effective single dose of a CD20-specific binding molecule. ! 2. A method of treating a person having or presumably having a rheumatic disease, comprising administering to a person a therapeutically effective single dose of a CD20 specific binding molecule. ! 3. The method according to claim 2, where the rheumatic disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, dermatomyositis, Shenlein-Genoch disease, juvenile rheumatoid arthritis, psoriatic arthritis, Raynaud's syndrome, Reiter's syndrome, sarcoidosis, spondylitis, spondylitis, spondylitis, spondylitis and myositis. ! 4. The method according to claim 3, where the disease is rheumatoid arthritis. ! 5. The method according to claim 4, where the introduction of a CD20-specific binding molecule results in an ACR score of 20. equal to! 6. The method according to claim 4, where the number of b-cells in a biological sample of a person is reduced. ! 7. The method according to claim 4, where the expression of the RANK ligand in a biological sample of a person is reduced. ! 8. The method according to claim 6 or 7, where the biological sample is a blood, synovial fluid or synovial biopsy. ! 9. A method of treating a person having or presumably having an inflammatory intestinal disease, comprising administering to a person a therapeutically effective single dose of a CD20-specific binding molecule. ! 10. The method according to claim 9, where the inflammatory intestinal disease is selected from the group consisting of ulcerative colitis and Crohn's disease. ! 11. The method according to claim 10, |
priorityDate | 2005-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 290.